期刊文献+

Study on the expression and prognostic relationship of MYL6B in liver cancer based on bioinformatics

下载PDF
导出
摘要 BACKGROUND Primary liver cancer is a prevalent and deadly cancer type.Despite treatment advances,prognosis remains poor,with high recurrence rates.Early detection is crucial but challenging due to the disease’s insidious nature.Myosin proteins play significant roles in cancer development,influencing cell migration,invasion,and tumor suppression.MYL6B,a myosin light chain,is involved in various cellular processes and has been associated with poor prognosis in colorectal adenocarcinoma and potential as a biomarker in breast cancer.AIM To investigate the expression of MYL6B in liver hepatocellular carcinoma(LIHC)and its impact on prognosis and potential mechanisms of action using bioinformatics methods.METHODS The expression of MYL6B in pan-cancer and normal tissues was analyzed using the gene expression profiling interactive analysis 2 and tumor immune estimation resource databases.The expression level of MYL6B in LIHC tissues and its relationship with prognosis were analyzed,immunohistochemical analysis of MYL6B and its effect on immune cell infiltration,and the protein network were further studied.RESULTS MYL6B was highly expressed in diffuse large b-cell lymphoma,LIHC,pancreatic adenocarcinoma,skin cutaneous melanoma,thymoma,uterine corpus endometrial carcinoma,uterine carcinosarcoma,and lowly expressed in kidney chromophobe,acute myeloid leukemia,testicular germ cell tumors.The expression level of MYL6B was significantly different between cancer and normal tissues.It had a significant impact on both overall survival and disease-free survival.MYL6B is highly expressed in hepatocellular carcinoma and its expression level increases with cancer progression.High MYL6B expression is associated with poor prognosis in terms of overall survival and recurrence-free survival.The immunohistochemical level of MYL6B is high in hepatocellular carcinoma tissues,and MYL6B has a high level of immune infiltration inflammation.In protein network analysis,MYL6B is correlated with MYL2,MYL6,MYL9,MYLK4,MYLK2,MYL12A,MYL12B,MYH11,MYH9 and MYH10.CONCLUSION The expression level of MYL6B in LIHC was significantly higher than in normal liver tissues,and it was correlated with the degree of differentiation survival rate,and immune infiltration.MYL6B is a potential target for LIHC treatment.
出处 《World Journal of Clinical Oncology》 2024年第9期1188-1197,共10页 世界临床肿瘤学杂志(英文版)
  • 相关文献

参考文献1

二级参考文献12

  • 1Alejandro Forner,Josep M Llovet,Jordi Bruix.Hepatocellular carcinoma[J].The Lancet.2012(9822)
  • 2European Association for the Study of the Liver,European Organisation for Research and Treatment of Cancer.EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma[J].Journal of Hepatology.2012(4)
  • 3Wen-Tsan Chang,Wei-Yu Kao,Gar-Yang Chau,Chien-Wei Su,Hao-Jan Lei,Jaw-Ching Wu,Cheng-Yuan Hsia,Wing-Yiu Lui,Kuang-Liang King,Shou-Dong Lee.Hepatic resection can provide long-term survival of patients with non–early-stage hepatocellular carcinoma: Extending the Indication for resection?[J].Surgery.2012(5)
  • 4Andrea Ruzzenente,Alfredo Guglielmi,Marco Sandri,Tommaso Campagnaro,Alessandro Valdegamberi,Simone Conci,Fabio Bagante,Gianni Turcato,Mirko D’Onofrio,Calogero Iacono.Surgical Resection Versus Local Ablation for HCC on Cirrhosis: Results from a Propensity Case-Matched Study[J].Journal of Gastrointestinal Surgery.2012(2)
  • 5Guido Torzilli,Jacques Belghiti,Norihiro Kokudo,Tadatoshi Takayama,Lorenzo Capussotti,Gennaro Nuzzo,Jean-Nicolas Vauthey,Michael A. Choti,Eduardo De Santibanes,Matteo Donadon,Emanuela Morenghi,Masatoshi Makuuchi.A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral Centers: Is It Adherent to the EASL/AASLD Recommendations?: An Observational Study of the HCC East-West Study Group[J].Annals of Surgery.2013(5)
  • 6Beom Kyung Kim,Seung Up Kim,Jun Yong Park,Do Young Kim,Sang Hoon Ahn,Mi Sung Park,Eun Hye Kim,Jinsil Seong,Do Youn Lee,Kwang‐Hyub Han.Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long‐term clinical outcomes of 1717 treatment‐na?ve patients with hepatocellular carcinoma[J].Liver Int.2012(7)
  • 7Manal M. Hassan,Ahmed Kaseb,Carol J. Etzel,Hashem El‐Serag,Margaret R. Spitz,Ping Chang,Katherine S. Hale,Mei Liu,Asif Rashid,Mohamed Shama,James L. Abbruzzese,Evelyne M. Loyer,Harmeet Kaur,Hesham M. Hassabo,Jean‐Nicolas Vauthey,Curtis J. Wray,Basmah S. Hassan,Yehuda Z. Patt,Ernest Hawk,Khalid M. Soliman,Donghui Li.Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: Risk and prognosis prediction[J].Mol Carcinog.2013(S1)
  • 8A. Thelen,C. Benckert,H.‐M. Tautenhahn,H.‐M. Hau,M. Bartels,J. Linnemann,J. Bertolini,M. Moche,C. Wittekind,S. Jonas.Liver resection for hepatocellular carcinoma in patients without cirrhosis[J].Br J Surg.2012(1)
  • 9Roberto Santambrogio,Michael D. Kluger,Mara Costa,Andrea Belli,Matteo Barabino,Alexis Laurent,Enrico Opocher,Daniel Azoulay,Daniel Cherqui.Hepatic resection for hepatocellular carcinoma in patients with C hild– P ugh’s A cirrhosis: is clinical evidence of portal hypertension a contraindication?[J].HPB.2012(1)
  • 10Jing-Houng Wang,Chih-Chi Wang,Chao-Hung Hung,Chao-Long Chen,Sheng-Nan Lu.Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma[J].Journal of Hepatology.2011(2)

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部